235 related articles for article (PubMed ID: 15068500)
61. Pharmacological management of severe postmenopausal osteoporosis.
Gaudio A; Morabito N
Drugs Aging; 2005; 22(5):405-17. PubMed ID: 15903353
[TBL] [Abstract][Full Text] [Related]
62. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
63. [The role of raloxifene (Evista) in the treatment and prevention of postmenopausal osteoporosis].
Korsić M
Reumatizam; 2003; 50(2):55-7. PubMed ID: 15098379
[TBL] [Abstract][Full Text] [Related]
64. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
Mok CC; Ying KY; To CH; Ho LY; Yu KL; Lee HK; Ma KM
Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
[TBL] [Abstract][Full Text] [Related]
65. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study.
Silverman SL; Minshall ME; Shen W; Harper KD; Xie S;
Arthritis Rheum; 2001 Nov; 44(11):2611-9. PubMed ID: 11710717
[TBL] [Abstract][Full Text] [Related]
66. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
[TBL] [Abstract][Full Text] [Related]
67. Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene.
Ohta H; Uemura Y; Sone T; Tanaka S; Soen S; Mori S; Hagino H; Fukunaga M; Nakamura T; Orimo H; Shiraki M;
Calcif Tissue Int; 2023 Apr; 112(4):430-439. PubMed ID: 36707436
[TBL] [Abstract][Full Text] [Related]
68. Raloxifene and colorectal cancer.
Walsh JM; Cheung AM; Yang D; Litwack S; Grady D
J Womens Health (Larchmt); 2005 May; 14(4):299-305. PubMed ID: 15916502
[TBL] [Abstract][Full Text] [Related]
69. Fractal analysis of radiographic trabecular bone texture and bone mineral density: two complementary parameters related to osteoporotic fractures.
Benhamou CL; Poupon S; Lespessailles E; Loiseau S; Jennane R; Siroux V; Ohley W; Pothuaud L
J Bone Miner Res; 2001 Apr; 16(4):697-704. PubMed ID: 11315997
[TBL] [Abstract][Full Text] [Related]
70. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
71. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia.
Seeman E; Devogelaer JP; Lorenc R; Spector T; Brixen K; Balogh A; Stucki G; Reginster JY
J Bone Miner Res; 2008 Mar; 23(3):433-8. PubMed ID: 17997711
[TBL] [Abstract][Full Text] [Related]
72. Raloxifene reduces fractures in postmenopausal women with osteoporosis.
Reginster JY; Devogelaer JP
Clin Orthop Relat Res; 2006 Feb; 443():48-54. PubMed ID: 16462425
[TBL] [Abstract][Full Text] [Related]
73. A method for determining the grade of osteoporosis based on risk factors in postmenopausal women.
Ofluoglu D; Gunduz OH; Bekirolu N; Kul-Panza E; Akyuz G
Clin Rheumatol; 2005 Nov; 24(6):606-11. PubMed ID: 16010446
[TBL] [Abstract][Full Text] [Related]
74. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study.
Levy C; Harnois DM; Angulo P; Jorgensen R; Lindor KD
Liver Int; 2005 Feb; 25(1):117-21. PubMed ID: 15698408
[TBL] [Abstract][Full Text] [Related]
75. Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
Uemura Y; Sone T; Tanaka S; Miyazaki T; Tsukiyama M; Taguchi A; Soen S; Mori S; Hagino H; Sugimoto T; Fukunaga M; Ohta H; Nakamura T; Orimo H; Shiraki M;
Curr Med Res Opin; 2020 Nov; 36(11):1847-1859. PubMed ID: 32870712
[TBL] [Abstract][Full Text] [Related]
76. Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography.
Genant HK; Lang T; Fuerst T; Pinette KV; Zhou C; Thiebaud D; Diez-Perez A
Bone; 2004 Nov; 35(5):1164-8. PubMed ID: 15542042
[TBL] [Abstract][Full Text] [Related]
77. Skeletal and nonskeletal effects of raloxifene.
Gluck O; Maricic M
Curr Osteoporos Rep; 2003 Dec; 1(3):123-8. PubMed ID: 16036075
[TBL] [Abstract][Full Text] [Related]
78. The effect of raloxifene on bone marrow adipose tissue and bone turnover in postmenopausal women with osteoporosis.
Beekman KM; Veldhuis-Vlug AG; den Heijer M; Maas M; Oleksik AM; Tanck MW; Ott SM; van 't Hof RJ; Lips P; Bisschop PH; Bravenboer N
Bone; 2019 Jan; 118():62-68. PubMed ID: 29032175
[TBL] [Abstract][Full Text] [Related]
79. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
80. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus.
Bultink IE; Lems WF; Kostense PJ; Dijkmans BA; Voskuyl AE
Arthritis Rheum; 2005 Jul; 52(7):2044-50. PubMed ID: 15986345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
